ABSTRACT
OBJECTIVE: To establish the fingerprint of the serum containing rhubarb bound anthraquinones, and to analyze the drug-originated constituents in serum containing drugs by serum pharmacochemistry. METHODS: Rat serum containing drugs were prepared after intragastric administration of the extract of rhubarb bound anthraquinones. Fingerprints of 10 batches serum containing drugs were determined by HPLC, and the common mode was established. Comparing the chromatogram of serum containing drugs with the one of blank serum, the common peaks of drug-originated constituents in blood were identified. Comparing the retention time and spectrum of the chromatographic peaks of serum containing drugs with the ones of extract, the sources of drug-originated constituents were analyzed. Comparing the retention time and spectrum of the chromatographic peaks of serum containing drugs with the ones of mixed reference substances, some drug-originated constituents were identified. RESULTS: There are 20 common peaks of drug-originated constituents in 10 batches serum containing drugs, 14 of them were in vitro prototype, and the other 6 were metabolites in vivo. Thirteen out of 14 prototype constituents were identified as aloe emodin-8-O-glucopyranoside, rhein-8-O-glucopyranoside, emodin-1-O-glucopyranoside, chrysophanol-1-O-glucopyranoside, chrysophanol-8-O-glucopyranoside, emodin-8-O-glucopyranoside, aloe emodin-3-CH2-O-glucopyranoside, physcion-8-O-glucopyranoside, aloe emodin, rhein, emodin, chrysophanol, and physcion, respectively. Other 1 prototype constituent and 6 metabolites possessed the same UV absorption character as that of anthraquinones. CONCLUSION: The method established in this study is accurate and feasible, and can be used for the analysis of the drug-originated constituents in serum containing rhubarb bound anthraquinones.
ABSTRACT
OBJECTIVE: To establish the fingerprint of the serum containing drug of Yinchenhao Decoction (YCHD), and analyze the drug-originated constituents in serum. METHODS: An HPLC method was set up on a Symmetry C18(4.6 mm × 250 mm, 5 μm) column with a Security Guard Cartridges C18 (4.0 mm × 3.0 mm) guard column by gradient elution of acetonitrile-0.1% phosphoric acid in water at the flow rate of 1.0 mL · min-1. The column temperature was maintained at 30℃. The detection was carried out at 238 and 440 nm. SD rats were taken as serum donors. Ten batches of serum containing drugs were prepared after ig administration of YCHD. The fingerprints of these serum samples were determined, the common modes were established, and the similarities between fingerprints were evaluated. Drug-originated constituents in blood were distinguished by comparing the fingerprint of serum containing YCHD with the one of control serum. The sources of drug-originated constituents were analyzed by comparing the fingerprint of serum containing YCHD with the ones of serum containing individual herbs of YCHD. Drug-originated constituents in blood were identified by comparing the retention time and UV spectra of peaks in fingerprint of serum containing YCHD with the ones of YCHD and reference substances, respectively. RESULTS: The similarities between the fingerprints of ten batches of serum containing YCHD and common models at 238 and 440 nm were greater than 0.904 and 0.903, respectively. Twenty common peaks of drug-originated constituents were identified in the fingerprints of serum containing drug of YCHD at 238 and 440 nm. Out of them, six were the original compounds, the other 14 were metabolites. Three constituents out of six original form ones were identified as geniposidic acid and genipo-side (iridoids originated from GF), and rhein (anthraquinone from RRR), and the other three were identified as an anthraquinone from RRR and two crocetin derivatives from FG. Out of 14 metabolites, one was identified as the metabolite of iridoid, four were from anthraquinone, and nine were from crocetin derivatives. CONCLUSION: The established method is accurate, reliable and can be used for the analysis of drug-originated constituents in serum containing drug of YCHD.